Merck Eshmuno P anti-A and anti-B chromatography resins

Monday, 25 September, 2017 | Supplied by: Merck Pty Ltd

Merck has launched the Eshmuno P anti-A and Eshmuno P anti-B affinity chromatography resins, specifically designed to remove anti-A and anti-B isoagglutinin antibodies during the manufacturing of plasma-derived immunoglobulin (Ig) therapies.

Trace amounts of anti-A and anti-B antibodies in plasma-derived Ig can lead to serious and sometimes fatal haemolytic events in patients undergoing plasma-based treatment. The introduction of chromatographic steps using Eshmuno P resins to deplete anti-A and anti-B antibodies is expected to reduce patient risk for adverse medical events associated with plasma-derived Ig therapies. This enhanced patient safety is achieved without negatively impacting process economics by re-using the resins for at least 200 cycles, with acid or alkaline cleaning, without loss of performance.

The resins are manufactured using a combination of Merck’s base matrix technology and a novel synthetic approach. The resins are released by an innovative test method to evaluate performance with less variability compared with classical agglutination methods, according to the company.

Merck’s chromatography resins are designed for efficient bioprocessing purification and are extensively used in commercial processes. The resins can be used to support plasma purification processes while minimising operational costs and time to clinic.

Phone: 1800 335 571
Related Products

JEOL JSM-IT800 Schottky field emission scanning electron microscope

JOEL's JSM-IT800, with the Intelligence Technology (IT) platform, incorporates the...

Thorlabs Chrolis 6-Wavelength High-Power LED Source

Thorlabs' Chrolis 6-Wavelength High-Power LED Source is a 6-colour light engine for...

Bio-Rad Laboratories GelDoc Go Imaging System

Bio-Rad Laboratories has launched its GelDoc Go Imaging System — a personal benchtop system...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd